Genotyping and Infection Rate of GBV-C among Iranian HCV- Infected Patients by Ghanbari, Reza et al.
ORIGINAL
 A RTICLE
Hepatitis Monthly 2010; 10(2): 80-87
Genotyping and Infection Rate of GBV-C among
Iranian HCV-Infected Patients
Reza Ghanbari 1, Mehrdad Ravanshad 1*, Seyed Younes Hosseini 1, Ramin Yaghobi 2, Kiana Shahzamani 1
 1 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2 Department of Virology, Shiraz Transplant Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Introduction
T
he GB virus C (GBV-C) and hepatitis G virus 
(HGV) were independently discovered (1, 2), 
but it was later determined that they were two isolates 
of the same virus (3, 4). Since subsequent studies did 
not find an association between these viruses and 
hepatitis, most researchers refer to the virus as GBV-C 
(5). The GBV-C is a single-stranded, positive-sense 
RNA virus, a member of the Flaviviridae (1, 2). Based 
on a comparison between genome organization and 
sequence homologies, GBV-C is most closely related 
to human hepatitis C virus (HCV), another member 
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Background and Aims: Hepatitis G virus/GB virus-C (HGV/GBV-C) is a newly identified member of the Flaviviridae family. 
Its clinical significance in chronic hepatitis C infection remains controversial. There is a geographical difference in the 
distribution of GBV-C in the world. The frequency of GBV-C infection among hepatitis C virus (HCV) infected patients 
varies. The aim of the current study was to determine the prevalence and genotypes of GBV-C among Iranian patients 
infected with chronic HCV.
Methods: Infection with GBV-C was surveyed in 71 chronic confirmed hepatitis C infected patients. These samples were 
collected at the Digestive Disease Research Center (DDRC) of Shariati Hospital, Tehran, Iran from January to October 
2007. The 5’-UTR region of GBV-C RNA was detected using a novel in-house touchdown nested reverse transcription 
polymerase chain reaction (RT-PCR), the products were sequenced and the results were aligned and phylogenically 
analyzed.
Results: Of the 71 HCV-infected patients, 31 (43.6%) were found positive for GBV-C RNA. Sequencing and phylogenic 
analysis showed that the samples were Genotype 2 of GBV-C. 
Conclusions: It seems that there is a high rate of GBV-C infection among Iranian patients infected with chronic HCV. In 
comparison with the six reference genotypes, it was observed that all the samples were categorized in Genotype 2 of 
GBV-C, prevalent in North America, Africa and in European countries. 
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of  the  Flaviviridae  (1,  6)  However,  in  contrast  to 
HCV, GBV-C does not appear to be hepatotrophic 
(7, 8). In fact, GBV-C replicates within the cells of the 
hemopoietic lineage and lymphocytes (9). Based on 
sequence and phylogenetic analysis, it was observed 
that different genotypes of HCV differ by more than 
30%, while the most extreme GBV-C variants differ 
by only 14% (10).
GBV-C is transmitted through blood transfusion 
and components (11-13). Epidemiological data suggest 
that the virus is also spread by sexual and vertical modes 
of transmission (14-16). GBV-C infection is relatively 
common and prevalent all over the world. Between 
1% and 4% of healthy blood donors have GBV-C 
RNA detected in their sera (7, 17, 18). It is prevalent in 
high-risk groups, such as people with hemodialysis, 
hemophiliacs,  HCV,  human  immunodeficiency 
virus (HIV), and hepatitis B virus (HBV) infected 
patients, as well as in intravenous drug users. 
A number of studies have shown that GBV-C 
has a profound “protective” influence on HIV and 
inhibits replication of this virus in vitro, and has 
been associated with a decreased risk of death and 
better  response  to  treatment  among  HIV-positive 
persons as far as co-infection is concerned(19-23). Co-
infection of GBV-C and HCV is common. Among 
newly diagnosed cases of blood-borne viral hepatitis 
in the United States, 18% were found positive for 
GBV-C, and 80% of these patients were also infected 
with  HCV  (24).  Other  studies  have  reported  the 
incidence of GBV-C co-infection with HCV, varying 
from  11–31.5%  (3,  25-28).  The  high  prevalence 
of HCV infection and its morbidity, as well as its 
relation to acute and chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma is very well documented. 
As for GBV-C, there is little evidence of morbidity 
and many doubts about its etiological role in liver 
diseases in situations of co-infection with HCV or 
HBV (5, 29-31). Most of the studies on GBV-C in 
Iran have been done on HIV co-infected patients, 
and the GBV-C infection-rate was reported to be 
10.97% (32), 11.3% (33) and 15.5% (34). In another 
study,  13%  of  Iranian  hemodialysis  patients  were 
also found to be infected with GBV-C (35). 
The aim of the current study was to determine the 
rate of co-infection of GBV-C and HCV, as well as 
the genotype distribution of GBV-C among Iranian 
patients infected with chronic HCV. 
Based on a variation in the nucleotide sequence 
of  5’-untranslated  region  (5’-UTR),  GBV-C  can 
be classified into six major genotypes  (36-38) .The 
GBV-C  genotypes  were  described  as  originating 
in West Africa (Genotype 1), North America and 
Europe (Genotype 2), East Asia and Japan (Genotype 
3),  Southeast  Asia  (Genotype  4),  South  Africa 
(Genotype 5), and a recently discovered genotype 
in Indonesia (Genotype 6). It was also shown that 
different  genotypes  have  different  geographical 
distribution (36, 38-40). Apart from the six genotypes 
of human GBV-C, a closely related chimpanzee virus 
“GBV-C tro” was also discovered (41).
Although  some  studies  have  reported  that 
Genotypes 3 and 4 are prevalent in most parts of 
Asia (10, 42, 43), our study showed that Genotype 2 of 
GBV-C is most prevalent in HCV-infected patients 
in Iran (33, 35, 44), as previously reported in the United 
Arab of Emirates (45) and Turkey (46). In the current 
study, 27 GBV-C isolates from Iranian individuals 
infected  with  chronic  HCV  were  sequenced  and 
analyzed to determine the GBV-C genotype.
Materials and Methods
Patients 
Seventy  one  Iranian  chronic  HCV  infected 
patients, in total, who had all been referred to the 
Digestive  Disease  Research  Center  (DDRC)  of 
Shariati Hospital, Tehran, Iran for treatment, were 
randomly selected for the study during the period 
January to October 2007. These patients were from 
different parts of Iran. The study and sampling was 
approved  by  Tarbiat  Modares  University’s  Ethics 
Approval  Committee,  and  informed  consent  was 
obtained  from  the  patients.  All  of  the  samples 
were  analyzed  with  Amplicor  HCV  test  v2.0 
(Roche  Diagnostics,  Germany),  according  to  the 
manufacturer’s instructions, and HCV genotypes were 
determined based on the HCV genome sequencing 
of 5’-UTR regions by the restriction fragment length 
polymorphism (RFLP) method at Keivan Laboratory. 
The collected sera were stored at -70ºC in an HCV 
sample bank. The samples consisted of 16 females 
and 55 males in age ranging from 19 to 57 years old. 
All of the sera samples were used for RNA extraction, 
reverse transcription, polymerase chain reaction, and 
sequencing. 
Amplification of GBV-C sequence 
  GBV-C  RNA  was  detected  by  an  in-house 
developed  touchdown  nested  reverse  transcription 
polymerase chain reaction (RT-PCR), using nested 
primers targeting the 5’-UTR region (Table 1). 
Briefly, the total viral RNA was extracted from 140 
µl of serum using the QIAamp Viral RNA Kit (Qiagen, 
Germany), according to the manufacturer’s instructions. Hepatitis Monthly, Spring 2010; 10(2): 80-87
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Complementary DNA (cDNA) was synthesized from 
2 µl of extracted RNA at 25°C for 5 min, at 42°C for 
1 h, and at 72°C for 10 min, using Moloney Murine 
Leukaemia virus reverse transcriptase (M-MuLV-RT), 
and random hexamers. Each 20 µl RT master mixture 
contained 1 mmol dNTP, 0.01 mg/ml hexanucleotide, 
7.5  U/ml  M-MuLV-reverse  transcriptase,  1  U/ml 
RNase inhibitor, and 4 µl 5X RT buffer.
Based on the reference sequences from GenBank, 
oligonucleotide-specific  nested  primer  pairs  were 
designed to amplify the 5’-untranslated region (5’-
UTR), and the final expected product was 188 bp in 
length (Table 1). Two microliters of produced cDNA 
were used as a template for the first round, and one 
microliter of the first- round PCR product was used 
for the second.
For the first PCR round, the PCR master mixture 
contained: 0.15 pmol/ul primers, 0.2 mmol dNTPs, 
1.25U Taq DNA polymerase, 2.5 µl 10× PCR buffer, 
and 1.5 mmol MgCl2. The reagents for the second 
PCR round were the same as the ones used in the 
first round. The total volume per reaction in the two 
rounds was 25 µl. 
Amplification was done in 25 cycles for the first 
round (94°C for 50 s, 55°C for 40 s, 72°C for 50 s 
with a final extension at 72°C for 3 min followed by 
a hold at 4°C) and 30 cycles for the second rounds 
of PCR (94°C for 40 s, 53°C for 35 s, 72°C for 40 s 
with a final extension at 72°C for 3 min followed by 
a hold at 4°C). 
All  PCR  contamination  precautions  were 
observed;  and  negative  controls  using  sera  from 
subjects with no GBV-C markers was obtained from 
the Iranian Blood Transfusion Organization Research 
Center. PCR procedure was carefully optimized. 
To remove small traces of non-specific bands, a 
touchdown procedure was adopted for the second 
round (94°C for 50 s, 72°C for 70 s, 8 cycles; 94°C 
for 40 s, 69°C for 35 s, 72°C for 40 s, 5 cycles; 94°C 
for 40 s, 67°C for 35 s, 72°C for 40 s, 5 cycles; 94°C 
for 40 s, 64°C for 35 s, 72°C for 40 s, 8 cycles; 94°C 
for 40 s, 62°C for 35 s, 72°C for 40 s, 4 cycles; and 
the final extension 72°C for 2 min followed by a 
hold at 4°C). The PCR products were analyzed by 
electrophoresis in a 2% agarose gel and stained with 
ethidium bromide (Fig. 1).
Finally, the product band was selected and purified 
with  the  AccuPrep  Gel  Purification  Kit  (Bioneer, 
Korea), and the optical density was measured. 
PCR  products  were  directly  and  bidirectionally 
sequenced using a BigDye Terminator cycle sequencing 
kit  (Applied  Biosystems,  CA,  USA)  with  an  ABI 
PRISM 3700 DNA analyzer automated sequencer at 
Sequence Laboratories Göttingen GmbH (SEQLAB), 
Germany.
Randomization  to  either  the  TACE  with 
gemcitabine  plus  oxaliplatin  combination  group 
(GO  group)  or  the  TACE  with  floxuridine  plus 
oxaliplatin  combination  group  (FO  group)  was 
performed  without  stratification  by  drawing 
consecutively  numbered  sealed  envelopes.  The 
protocol was approved by the ethics committee of 
Fujian Provincial Tumor Hospital. Written informed 
consent was obtained.
Reference sequences from the database
In total, 30 reference sequences of GBV-C Genotype 
1–6 were obtained from GenBank and were used to 
compare  the  sequences  of  the  isolates  in  the  study. 
The accession numbers of the reported sequences and 
country of the reported sequences were as following: 
Genotype  1,  U36380  (USA),  AB013500  (Ghana), 
Table 1. Primer sequences and product length for 5'-UTR region of GBV-C. 
Primer Primer Sequence Product length
GBV-C-G1 (sense, outer) 5’-GGTCGTAAATCCCGGTCACC-3’
262bp
GBV-C-G2 (anti-sense, outer) 5’-CCCACTGGTCCTTGTCAACT-3’
GBV-C-G3 (sense, inner) 5’-TAGCCACTATAGGTGGGTCT-3’
188bp
GBV-C-G4 (anti-sense, inner) 5’-ATTGAAGGGCGACGTGGACC-3’
Figure 1. Agarose gel electrophoresis of PCR 
products. From left: lane 1 and 2 negative 
samples; lane 3 DNA ladder (100 bp); lane 4 
and 5 positive samples (Touchdown RT-PCR); 
lane 6 and 7 positive samples (Conventional 
RT-PCR).Hepatitis Monthly, Spring 2010; 10(2): 80-87
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AB003291  (Japan);  Genotype  2,  U44402  (USA), 
AF121950  (USA),  AX338086  (USA),  AF081782 
(China),  AF309966  (Germany),    D87255  (Japan), 
AF031827 (USA), AF031829 (USA), U45966 (USA), 
AF104403  (France),  AB003289  (Japan),  D90600 
(Japan), AB013501 (Bolivia), U63715 (East Africa), 
AF172543  (South  Africa);  Genotype  3,  D90601 
(Japan), D87262 (Japan), AF006500 (Hong Kong), 
AB013501  (Japan),  AB003293  (Japan),  AB003288 
(Japan), D87253 (Japan), D87252 (Japan); Genotype 
4,  AB018667  (Vietnam),  AB021287  (Myanmar); 
Genotype 5, AF131112 (South Africa); Genotype 6, 
AB003292 (Japan); AF070476 (GBV-C tro).
Phylogenetic analysis
Phylogenetic analysis was performed, based on 
GBV-C  5’-UTR  nucleotide  sequence  and  related 
reference sequences. All of the results were edited 
and  first  analyzed  with  Bioedit  (Ibis  Biosciences, 
USA), and ClustalX (EMBL-EBI, UK) software for 
multiple alignments. 
Genetic distance was estimated using the Kimura-
two-parameter matrix (47). Phylogenetic trees were 
constructed by the neighbor-joining (NJ) method 
(48). Bootstrap resampling and reconstruction were 
carried out on 100 replicates to ensure consistency. 
The analysis and calculation of nucleotide differences 
within  and  between  the  isolate  sequences  were 
carried out using MEGA4 for Windows (Biodesign 
Institute, USA) software (Fig. 2). 
Results
 GBV-C RNA was detected in 31 (43.6%) out 
of  the  71  Iranian  patients  with  chronic  hepatitis 
C infection. Among the 71 patients with chronic 
hepatitis  C,  there  were  no  significant  differences 
in  sex  (P  =  0.393),  age  (P  =  0.260),  and  HCV 
genotypes in Iran (1a and 3a) (P = 0.471) in those 
with and without the GBV-C infection. The samples 
consisted of 16 (22.5%) females, 6 of them positive 
for GBV-C RNA, and 55 (77.5%) males, 25 of them 
positive for GBV-C RNA, with an age range of 19–
57 years old (Table 2). Four out of the 31 5’-UTR 
sequenced  were  excluded  because  of  unacceptable 
sequencing results.
The  neighbor-  joining  method  based,  using  a 
1000  bootstrap  re-sampling  replicate  tree,  on  the 
27  5’-UTR  nucleotide  sequences  of  patients  on 
whom  successful  amplification  and  sequencing 
were performed. Also 30 different reference GBV-C 
isolates in the GenBank database were included.
The results also showed that Genotype 2 is the 
most prevalent in infected patients. Based on the 
results, the Iranian isolates were classified as Genotype 
2 with a bootstrap value of >80% based on clustering 
with  previously  characterized  Genotype  2  isolates 
and other genotypes (Fig. 2). 
Discussion
In the current study, GBV-C RNA was detected 
in 43.6% of Iranian patients infected with chronic 
HCV.  Other  studies  on  GBV-C  have  reported  a 
relatively lower prevalence. Tanaka et  al. demonstrated 
GBV-C and HCV coinfection in 11% of patients 
with chronic HCV  (27), Alter et al. described this 
coinfection in 20% (3), Martinol et al. found GBV-C 
infection in 21% of patients with chronic HCV (26), 
Feucht et al. found GBV-C infection in 24.4% of 
HCV-infected patients (25), and Jie Yan et al., Sauleda 
S et al. and Quiros E et al. described this coinfection, 
respectively, in 31.5%, 21%, and 19% of patients 
with chronic HCV (28, 49, 50). Al-knawy et al. also 
demonstrated the GBV-C in 31% of Saudi Arabian 
Table 2. Demographic characteristics of HCV-infected and HCV, GBV-C co-infected patients.
Patients’ characteristics Total patients Number of HCV infected patients Number of HCV and GBV-C co-infected patients
Patients’ Sex Male
Female
55
16
30
10
25
6
Patients’ Age Groups 
(years)
17-27
28-37
38-47
48-57
13
24
22
12
7
13
14
6
6
11
8
6
HCV Genotype
1a
3a
1b
1a + 1b
1a + 3a
4
30
28
5
5
2
1
19
18
1
1
-
1
11
10
4
4
2
-Hepatitis Monthly, Spring 2010; 10(2): 80-87
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Figure 2. Phylogenetic tree constructed using the Kimura two-parameter matrix and 
neighbor-joining method, based on 5'-UTR sequence (188nt, residues 163 – 350). 
References 5’-UTR sequence from GBV-C genomes are identified by their GenBank 
accession numbers. 12 out of 27 Iranian sequences determined in this study are 
indicated by the HG.IR prefix. The numbers 1-6 designated GBV-C genotypes.Hepatitis Monthly, Spring 2010; 10(2): 80-87
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HCV-infected patients (51). 
The aforementioned studies have shown a wide 
variation and a difference in prevalence in different 
geographical  areas.  The  difference  between  the 
GBV-C infection-rate, in earlier studies and in the 
current investigation, may be due to the size of the 
study group, the methods used to detect GBV-C, 
the  demographic  and  clinical  features  of  patients, 
the virulence of different genotypes and strains, and 
the different patterns of transmission of virus in the 
world (e.g., blood and blood components, sexual, 
intravenous  injection,  etc.).  Another  preliminary 
study  in  Iran  reported  the  prevalence  of  GBV-C 
among  Iranian  chronic  HCV-infected  patients, 
about 40% in a smaller study population (52). 
The genotypic classification of GBV-C has been 
extended to six genotypes (1 to 6) based on the 5’-
UTR,  and/or  E2  gene  sequences.  Earlier  studies 
have  suggested  that  the  phylogenetic  relationship 
of GBV-C complete genome sequences can also be 
reproduced by analysis of the 5’-UTR region (37, 40). 
The  GBV-C  genotypes  have  distinct  geographical 
distributions (40). Based on the sequence of Residue 
163–350 of the 5’-UTR region of Iranian GBV-C 
isolates, this study found that Genotype 2 seems to 
be the most common. 
Despite  the  fact  that  little  is  known  about  the 
GBV-C genotype in the Middle East/Mediterranean 
region, and despite the lack of significant information 
on GBV-C sequence(s) from this region, it is reported 
that Genotype 2 is common. A survey in Turkey has 
revealed that the predominant genotype is Genotype 2 
(46). In the United Arab Emirates, Abu Odeh et al. have 
also reported that Genotype 2 was the most prevalent 
among nationals and non-nationals alike (45).
To date, there is no information about the GBV-C 
sequences in Iranian patients infected with chronic 
HCV, and the current study reports the distribution 
of the GBV-C genotype based on 5’-UTR sequence 
and  phylogenetic  analysis  in  Iran.  Twenty-seven 
GBV-C strains were isolated from Iranian chronic 
HCV-infected  patients  and  were  successfully 
sequenced.  In  phylogenetic  analysis  based  on  5’-
UTR sequences, Genotype 2 in Iranian isolates was 
observed  with  significant  bootstrap  values.  In  all 
phylogenetic trees based on this region, the Iranian 
isolates were closely related to the strains in North 
American and European countries. 
Similar  molecular  epidemiology  surveys  have 
been  conducted  for  HCV  genotyping  in  Iran.  In 
all  of  these  studies,  HCV  genotypes  have  been 
determined based on HCV genome sequencing of 5’-
UTR regions. Their data have shown that different 
HCV genotypes are distributed in Iran. The most 
prevalent HCV genotypes were 1a and 3a, and the 
less prevalent ones were 3b and 4 (53).
In  summary,  our  findings  indicated  that  the 
prevalence  of  GBV-C  in  Iranian  patients  with 
chronic HCV is notably high. The high prevalence of 
GBV-C among Iranians with chronic HCV infection 
probably reflects similar modes of transmission and 
risk factors, both intravenously and through exposure 
to blood and blood products, probably since it is 
not  recommended  practice  to  screen  blood  units 
for HGV. The study also showed that Genotype 2 
of GBV-C is the most common genotype among 
Iranian chronic HCV-infected patients.
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